Amylin Starts Phase IIb Obesity Trial
Posted on: Tuesday, 6 May 2008, 06:00 CDT
Amylin Pharmaceuticals has initiated a Phase IIb clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin, and recombinant human leptin for the treatment of obesity.
The objective of this dose-ranging study is to support dose selection for Phase III, and to inform the ongoing development of a convenient delivery system for this combination regimen. The six-month, randomized, double-blind, placebo-controlled multi-center study will enroll approximately 600 overweight and obese subjects and is expected to complete in mid-2009.
The study will include a broad range of overweight and obese subjects (body mass index 27 to 45 kg/m2) and will compare various pramlintide/metreleptin combination regimens with each compound alone and with placebo.
Christian Weyer, vice president of clinical research, Amylin, said: "Building upon the positive results of our translational research program published in Proceedings of the National Academy of Sciences (PNAS), and the extensive clinical experience with both pramlintide and metreleptin as monotherapies, the newly initiated Phase IIb study will bring us one step closer to our goal of offering obese individuals a safe and effective therapy that results in meaningful weight loss."
Source: Datamonitor
Related Articles
- Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
- Genaera Reports Positive Data From Phase I Study of Diabetes and Obesity Drug
- Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
- Athersys Announces Summary Results for Phase 1 Safety Study of Its Novel Obesity Drug; ATHX-105 Exhibits Safety and Tolerability in Single and Multidose Studies
- Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study
- IBC Expands Coverage of Case Studies and Projects in Preclinical, Phase 1 and Phase 2
- Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials
- FermaVir Announces FDA Response to Its Pre-IND Submission for Initial Bioavailability Studies in Human Clinical Trials of FV-100; Response Enables Company to Plan Clinical Development Program for Novel Antiviral Drug Candidate
- Study: Risks Jump As Obesity Escalates
- Endpoints Met in First Stage of ADVENTRX CoFactor Phase II Metastatic Colorectal Cancer Study; Patient Enrollment Completed in Phase II Study
 |
 |
User Comments (0)
RSS Feeds